Gentamicin Surgical Implant (US)
Innocoll's CollaRx® Gentamicin Surgical Implant is currently in phase III clinical development in the US for the prevention of surgical site infections (SSIs) in patients at risk of infection.
According to the latest (2005) statistics published by the Pennsylvania Health Care Cost Containment Council (PHC4), one of the few US States mandated to collect such data, patients that contracted a surgical site infection spent an average of 14.5 days in hospital at an average hospital charge of $132,110 compared to 4.7 days and $33,267 for patients that had no hospital-acquired infection.
The same official report states that "surgery performed on the large and small intestines represented the largest percentage of surgical site infections at 9.0% followed closely by surgery for blockages in blood vessels, including blood vessels of the heart, which accounted for 8.9%".
The product is approved for sale in 61 countries (excluding the US) across Europe, Latin America, Middle East, Africa and Asia for the treatment and/or prevention of surgical site infections.
Colorectal study training video
For more information on this product, or to discuss partnership opportunities, please contact our business development team.